Kisqali (ribociclib) for HR+, HER2- Metastatic Breast Cancer

rethink_breast_cancer

****Breastcancer.org Moderators have approved this posting. Please note that Breastcancer.org is NOT responsible for, and is not endorsing any studies.****

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer (www.rethinkbreastcancer.com) – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.

The Canadian government will soon be reviewing the use of Kisqali to treat HR-positive, HER2-negative advanced or metastatic breast cancer and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.

Does this survey apply to you?

We are looking for woman with HR-positive, HER2-negative advanced or metastatic breast cancer and women who have been treated with Kisqali (ribociclib) to talk about their treatment experience.

YOU DO NOT NEED TO LIVE IN CANADA TO PARTICIPATE.

If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/kisqalisurvey

If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.

MJ DeCoteau

Founder + Executive Director

Rethink Breast Cancer

rethink_breast_cancer

Hi All,

This is a bump. We will continue to collect patient feedback for another ten days.

We welcome feedback from any HR+, HER2- metastatic breast cancer patients who have been treated with Kisqali, but we are especially interested in speaking with postmenopausal women who were treated with Kisqali in combination with Faslodex (fulvestrant).

Please complete the survey or send me a message if you would be willing to talk about your experience - https://www.surveymonkey.com/r/kisqalisurvey

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

MJ DeCoteau

2020Division

I have just started on the Kisqali and fulvestrant combo. I'm 45yo with mets to bones and lungs. Very slow-growing which is good. HR+, HER2-. I am keeping a journal of side effects and progress.